Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy

Basic and Clinical Pharmacology and Toxicology

Volumn 107, Issue 1, 2010, Pages 570-576

  Afsar, Nasir Ali ^a   Haenisch, Sierk ^b   Mateen, Ahmed ^c   Usman, Ahmed ^d   Ufer, Mike ^b   Ahmed, Khwaja Zafar ^a   Ahmad, Hakimuddin Razi ^a   Cascorbi, Ingolf ^b  

^a ZIAUDDIN UNIVERSITY   (Pakistan)

^b UNIVERSITY OF KIEL   (Germany)

^c Karachi Institute of Radiotherapy & Nuclear Medicine   (Pakistan)

^d JINNAH POSTGRADUATE MEDICAL CENTRE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 3A1; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DOXORUBICIN; DRUG METABOLIZING ENZYME; FLUOROURACIL; GLUTATHIONE TRANSFERASE A1; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; ALDH3A1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CYP2C9 PROTEIN, HUMAN; GLUTATHIONE TRANSFERASE; GSTA1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PAKISTAN; PRIORITY JOURNAL; PYROSEQUENCING; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; ANCESTRY GROUP; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DRUG INACTIVATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE;

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARYL HYDROCARBON HYDROXYLASES; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CONTINENTAL POPULATION GROUPS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2C9; DNA MUTATIONAL ANALYSIS; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; INACTIVATION, METABOLIC; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PAKISTAN; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 77953820594     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00531.x     Document Type: Article

References (30)

1. Ahern V, Brennan M, Ung O, Kefford R. Locally advanced and inflammatory breast cancer. Aust Fam Physician 2005 34 : 1027 1032.
2. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003 3 : 53 61. (Pubitemid 36432466)
3. Timm R, Kaiser R, Lötsch J, Heider U, Sezer O, Weisz K, et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 2005 5 : 365 373.
4. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In : Hardman JG, Limbird LE, Gilman AG (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics.
5. Rowe JD, Nieves E, Listowsky I. Subunit diversity and tissue distribution of human glutathione S-transferases: interpretations based on electrospray ionization-MS and peptide sequence-specific antisera. Biochem J 1997 325 : 481 486.
6. van Triest B, Pinedo HM, Telleman F, van der Wilt CL, Jansen G, Peters GJ. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. Biochem Pharmacol 1997 53 : 1855 1866.
7. Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005 112 : 3754 3762.
8. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996 6 : 341 349.
9. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 269 : 15419 15422.
10. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001 69 : 169 174.
11. Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 2008 18 : 357 365.
12. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003 33 (Suppl. 2 23 30.
13. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol 2005 19 : 101 105.
14. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002 41 : 913 958.
15. *17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 2009 115 : 391 396.
16. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007 101 : 113 121.
17. Ateş NA, Tamer L, Ateş C, Ercan B, Elipek T, Ocal K, et al. Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer. Biochem Genet 2005 43 : 149 163. (Pubitemid 40543712)
18. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF, et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 2003 103 : 810 814.
19. Lassen N, Bateman JB, Estey T, Kuszak JR, Nees DW, Piatigorsky J, et al. Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in Aldh3a1(-/-)/Aldh1a1(-/-) knock-out mice. J Biol Chem 2007 282 : 25668 25676.
20. Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, Ostmark B, et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer 2008 7 : 87. Doi: 10.1186/1476-4598-7-87.
21. Moreb JS, Mohuczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 2007 59 : 127 136.
22. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008 18 : 515 523.
23. Vasiliou V, Pappa A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. Pharmacology 2000 61 : 192 198.
24. Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh J, Bartelink IH, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit 2008 30 : 504 510.
25. Heggie GD, Sommadossi J-P, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolism in plasma, urine, and bile. Cancer Res 1987 47 : 2203 2206.
26. Blackhall FH, Howell S, Newman B. Pharmacogenetics in the management of breast cancer - prospects for individualised treatment. Fam Cancer 2006 5 : 151 157.
27. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008 26 : 2131 2138.
28. Süzen HS, Yüce N, Güvenç G, Duydu Y, Erke T. TYMS and DPYD polymorphisms in a Turkish population. Eur J Clin Pharmacol 2005 6 : 881 885.
29. Maekawa K, Saeki M, Saito Y, Ozawa S, Kurose K, Kaniwa N, et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 2007 52 : 804 819.
30. Gonzalez-Covarrubias V, Ghosh D, Lakhman SS, Pendyala L, Blanco JG. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab Dispos 2007 35 : 973 980.